Atypical antipsychotics in mood disorders

International Clinical Psychopharmacology

Volumn 17, Issue SUPPL. 3, 2002, Pages

  Kasper, Siegfried ^a   Stamenkovic, Mara ^a   Letmaier, Martin ^a   Schreinzer, Daniel ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atypical antipsychotics; Bipolar disorder; Mood disorders; Quetiapine

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; GABAPENTIN; HALOPERIDOL; IBUPROFEN; INDOMETACIN; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

AGRANULOCYTOSIS; ANTICONVULSANT ACTIVITY; ARTICLE; BIPOLAR DISORDER; BODY WEIGHT; CLINICAL FEATURE; COGNITIVE DEFECT; DISTRESS SYNDROME; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; EMPLOYMENT; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HEMORRHAGIC PANCREATITIS; HOSPITALIZATION; HUMAN; HYPOTHYROIDISM; INSOMNIA; KIDNEY DYSFUNCTION; LIVER FAILURE; LONG TERM CARE; MANIA; MOOD DISORDER; NAUSEA; NEUROMUSCULAR DISEASE; OUTCOMES RESEARCH; POLYURIA; PRIORITY JOURNAL; PROLACTIN RELEASE; PSYCHOSIS; RAPID CYCLING BIPOLAR DISORDER; RASH; REPRODUCTIVE TOXICITY; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SKIN DISEASE; SOCIAL STATUS; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREMOR; VERTIGO; WEIGHT GAIN;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; HUMANS; PATIENT CARE PLANNING; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SUICIDE;

EID: 0036701299     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J (1997). The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 9:1-17.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
3. Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P (1977). Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand 56:241-248.
4. Arvanitis LA, Miller BG (1997). Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42:233-246.
5. Bowden CL (1998). Key treatment studies of lithium in manic-depressive illness: Efficacy and side effects. J Clin Psychiatry 59(suppl. 6):13-19.
6. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F et al. (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 271:918-924.
7. Brady KT (2000). Difficulties in diagnosis and management of bipolar disorder: Three case presentations. J Clin Psychiatry 61(suppl. 13):32-37.
8. Brecher M, Rak IW, Westhead EK, Jones AM (2000). The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 4:287-292.
9. British National Formulary (2002). Edition Number 43, pp 186-187. London: British Medical Association and Royal Pharmaceutical Society of Great Britain.
10. Calabrese JR, Woyshville MJ (1995). Lithium therapy: Limitations and alternatives in the treatment of bipolar disorders. Ann Clin Psychiatry 7:103-112.
11. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY (1996). Clozapine for treatment-refractory mania. Am J Psychiatry 153: 759-764.
12. Calabrese JR, Rapport DJ, Shelton MD, Kujawa M, Kimmel SE (1998). Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology 38:185-191.
13. Compton MT, Nemeroff CB (2000). The treatment of bipolar depression. J Clin Psychiatry 61(suppl. 9):57-67.
14. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL (1993). The enduring psychosocial consequences of mania and depression. Am J Psychiatry 150: 720-727.
15. Craighead WE, Miklowitz DJ (2000). Psychosocial interventions for bipolar disorder. J Clin Psychiatry 61 (suppl. 13):58-64.
16. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999). Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Neuropsychopharmacology 20:491-505.
17. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM (2001). Quetiapine as adjunctive treatment for adolescent mania. Presented at the 2nd International Forum on Mood and Anxiety Disorders, Monte Carlo, Monaco, November 28-December 1, 2001.
18. Dilsaver SC, Swann AC, Shoaib AM, Bowers TC, Halle MT (1993). Depressive mania associated with nonresponse to antimanic agents. Am J Psychiatry. 150: 1548-1551.
19. Dunayevich E, McElroy SL (2000). Atypical antipsychotics in the treatment of bipolar disorder. CNS Drugs 13: 433-441.
20. Evans DL (2000). Bipolar disorder: Diagnostic challenges and treatment considerations. J Clin Psychiatry 61 (suppl. 13):26-31.
21. Ghaemi SN, Katzow JJ (1999). The use of quetiapine for treatment-resistant bipolar disorder: A case series. Ann Clin Psychiatry 11:137-140.
22. Ghaemi SN, Sachs GS (1997). Long-term risperidone treatment in bipolar disorder: 6-Month follow-up. Int Clin Psychopharmacol 12:333-338.
23. Glick ID, Suppes T, DeBattista C, Hu RJ, Marder S (2001). Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Intern Med 134:47-60.
24. Goldberg JF (2000). Treatment guidelines: Current and future management of bipolar disorder. J Clin Psychiatry 61(suppl. 13):12-18.
25. Goodnick PJ, Schorr-Cain CB (1991). Lithium pharmacokinetics. Psychopharmacol Bull 27:475-491.
26. Hellewell JSE, Goldstein J (1998). 'Seroquel' (quetiapine): Efficacy in improving mood, aggression and hostility. Presented at the Association of European Psychiatrists Congress, Copenhagen, September 20-24, 1998.
27. Hellewell JSE, Kalali AH, Langham SJ, McKellar J, Awad AG (1999). Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psych Clin Pract 3: 105-113.
28. Hirschfeld RM (2001). Bipolar spectrum disorder: Improving its recognition and diagnosis. J Clin Psychiatry 62(suppl. 14):5-9.
29. Jamison KR (2000). Suicide and bipolar disorder. J Clin Psychiatry 61(suppl. 9):47-51.
30. Kahn DA, Ross R, Printz DJ, Sachs GS (2000). Treatment of bipolar disorder: A guide for patients and families. Postgrad Med 107:1-8.
31. Kapur S, Remington G (1996). Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476.
32. Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S (1999). Dopamine- and serotonin-receptors in schizophrenia: Results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci 249(suppl. 4):IV/83-IV/89.
33. Kasper S, Tauscher J, Heiden A (2001). Quetiapine: Efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol 11(suppl. 4):S405-S413.
34. Kleinberg DL, Brecher M, Davis JM (1997). Prolactin levels and adverse events in patients treated with risperidone. Scientific Abstracts of the 150th Annual Meeting of the American Psychiatric Association, May 17-22, San Diego, California.
35. Lachman HM (2000). An overview of bipolar disorder: An inherited psychiatric disorder. Einstein Q J Biol Med 17: 135-142.
36. Letmaier M, Schreinzer D, Thierry N, Wolf R, Kasper S (2002). Pharmacological treatment pattern of mania in a natural setting: A retrospective chart study 1997-1999. Abstracts of the 15th Congress of the European College of Neuropsychopharmacology, Barcelona, 5-9 October, 2002.
37. Licht RW (2000). Typical and atypical antipsychotics in bipolar disorder. Acta Neuropsychiatrica 12:115-119.
38. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM (1994). The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 31:281-294.
39. Maj M, Pirozzi R, Kemali D (1989). Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology 98:535-538.
40. Manji HK, Lenox RH (2000). The nature of bipolar disorder. J Clin Psychiatry 61(suppl. 13):42-57.
41. McDonald WM (2000). Epidemiology, etiology, and treatment of geriatric mania. J Clin Psychiatry 61(suppl. 13): 3-11.
42. McElroy SL, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka R et al. (1998). Olanzapine in treatment-resistant bipolar disorder. J Affect Disord 49:119-122.
43. Nemeroff CB (2000). An ever-increasing pharmacopoiea for the management of patients with bipolar disorder. J Clin Psychiatry 61(suppl. 13):19-25.
44. Nolen WA, Bloemkolk D (2000). Treatment of bipolar depression, a review of the literature and a suggestion for an algorithm. Neuropsychobiology 42(suppl. 1):11-17.
45. Olanzapine prescribing information (2000). Physicians' Desk Reference (55th Edn), pp. 1788-1793. New Jersey: Medical Economic Company, Inc.
46. Owens DG (1994). Extrapyramidal side effects and tolerability of risperidone: A review. J Clin Psychiatry 55 (suppl.):29-35.
47. Perlick D, Clarkin JF, Sirey J, Raue P, Greenfield S, Struening E, Rosenheck R (1999). Burden experienced by care-givers of persons with bipolar affective disorder. Br J Psychiatry 175:56-62.
48. Poolsup N, Po LW, de Oliviera IR (2000). Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther 25:139-156.
49. Reddy YC, Srinath S (2000). Juvenile bipolar disorder. Acta Psychiatr Scand 102:162-170.
50. Sajatovic M, Brescan D, Perez D, DiGiovanni S (1999). Quetiapine in neuroleptic dependent mood disorders. 38th Annual Meeting of American College of Neuropsychopharmacology, Acapulco, Mexico 109:38.
51. Segal J, Berk M, Brook S (1998). Risperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial. Clin Neuropharmacol 21:176-180.
52. Simon GE, Unützer J (1999). Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 50:1303-1308.
53. Soares JC (2000). Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid cycling. Int Clin Psychopharmacol 15:183-196.
54. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ (1999). Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 156:1164-1169.
55. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa R, Daniel DG et al. 1999). Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 156: 702-709.
56. Woods SW (2000). The economic burden of bipolar disease. J Clin Psychiatry 61(suppl. 13):38-41.
57. Wyatt RJ, Henter I (1995). An economic evaluation of manic-depressive illness - 1991. Soc Psychiatry Psychiatr Epidemiol 30:213-219.
58. Zarate CA Jr, Tohen M, Baldessarini RJ (1995a). Clozapine in severe mood disorders. J Clin Psychiatry 56:411-417.
59. Zarate CA Jr, Tohen M, Banov MD, Weiss MK, Cole JO (1995b). Is clozapine a mood stabilizer? J Clin Psychiatry 56:108-112.